We care for the lives of patients by offering safe, effective, and innovative therapies with proven benefits on conditions such as bacterial infections, fungal infections, chemotherapy-induced emesis (vomiting) and new ways to treat acute pain.
Anti-infectives: bacterial and fungal infections
The widespread use of antibiotics and the lack of new therapeutic options for bacterial and fungal infections have caused an important worldwide problem due to the infections’ high morbidity and mortality. At Stendhal, we promote effective therapeutic options to combat multi-resistant strains.
Inpatient infections are frequently caused by gram-negative bacilli (Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii), which are increasingly more difficult to treat with conventional antibiotic therapies and require medicinal products capable of counteracting multi-drug resistance; likewise, a precise and reliable approach is required through therapies that guarantee wide-spectrum action and a formulation that ensures safety and minimum toxicity issues.
Invasive fungal infections (IFI) are an ever-growing issue in critically ill patients and are associated with an increased morbidity and mortality. The rate of IFI has increased significantly at a global level, which is a serious complication for hospitalized patients due to the major advances in contemporary medicine of the last few decades, especially for critical care patients; these advances have contributed not only to greater patient survival rates but also increased incidence of opportunistic fungal infections.
Nausea and vomiting caused by chemotherapy and radiation therapy can significantly affect the quality of life of cancer patients. These symptoms tend to occur in up to 30% of patients and are amongst the most common side effects. They can manifest within the first 72-96 hours following the administration of chemotherapy.
It is important to prevent nausea and vomiting with proper treatment during each chemotherapy cycle. Novel antiemetics tend to prevent acute and delayed nausea and vomiting caused by chemotherapy.
Thus, it is of utmost importance to include the most effective antiemetics in the therapeutic approach to treat chemotherapy-induced nausea.
Currently, one of the greatest therapeutic needs globally is pain management, due to its high prevalence and the impact it represents on patients' quality of life. It is known that unresolved pain can become chronic and affect not only the patient's physical well-being, but also their work, family and social spheres.
At Stendhal we are aware of this, which is why we currently have a specific therapeutic area for acute, moderate or severe pain, with drugs that contribute to its effective and safe treatment for patients. We keep in mind that one of the aspects to achieve therapeutic objectives in pain management is the appropriate choice of active ingredients and their pharmaceutical form, without leaving aside the quality and confidence in their production.